Cognitive FunctionNCT07766564
A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood
A study testing BrainJuice Supplement in people with Cognitive Function and Cognitive Performance, run by BrainJuice at 1 site in United States.
Trial summary
This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. Read more about this study
- Who is it for?
- Ages 18 to 57 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Function, Cognitive Performance, Mood
- What is being tested?
- BrainJuice Supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2025to 6 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 57 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be male or female
- Be aged 18-57
- Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease
- If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
- Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
Show all 10Show fewer
- Willing to maintain the same diet and exercise regimen consistently throughout the study duration
- Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
- Resides in the United States
- Has access to a computer or tablet device
Who cannot join
- Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
- History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
- History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
- History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
- Anyone with a job that involves shift work that may be overnight or night hours
- Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
Show all 12Show fewer
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Anyone unwilling to follow the study protocol
- Anyone with a history of substance abuse
- Anyone who is currently a smoker or has been a smoker in the past 3 months
- Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.
Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.
- Conditions
- Cognitive Function, Cognitive Performance, Mood
- Being tested
- BrainJuice Supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BrainJuice SupplementDietary supplement
All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm.
| Study group | Role | What they receive |
|---|---|---|
| BrainJuice Supplement | Experimental | Not described Receives: Dietary Supplement: BrainJuice Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cognitive Assessment Score (Polygons)
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Double Trouble)
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Feature Match)
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Paired Associates)
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Digit Span)
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
Measured: Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Spatial Planning)
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
Measured: Baseline, Week 2, Week 4, and Week 6
Secondary outcomes (10)
Change in Self-Reported Focus
Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Attention
Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Concentration
Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Productivity
Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Alertness
Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Clarity
Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mood
Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Fatigue
Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Motivation
Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Organization
Mean change in perceived organization from Baseline, assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start9 Nov 2025
- Primary completion6 Feb 2026
- Study completion6 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive FunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- BrainJuice
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07766564
- Sponsor's protocol ID
- 20807
- Other IDs
- legacy-20807
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood
- ClinicalTrials.gov ID
- NCT07766564
- Acronym / sponsor ID
- 20807
- Conditions
- Cognitive Function, Cognitive Performance, Mood
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- BrainJuiceIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 9 Nov 2025 (actual)
- Primary completion
- 6 Feb 2026 (actual)
- Study completion
- 6 Feb 2026 (actual)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.
Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| BrainJuice Supplement | Experimental | Dietary Supplement: BrainJuice Supplement |
Who may qualify
- Ages
- 18 to 57 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Be male or female
- Be aged 18-57
- Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease
- If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
Key exclusion criteria (12 listed)
- Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
- History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
- History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
- History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
- Anyone with a job that involves shift work that may be overnight or night hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BrainJuice SupplementAll participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm. | Dietary supplement | BrainJuice Supplement |
Primary outcome
Change in Cognitive Assessment Score (Polygons)
Time frame: Baseline, Week 2, Week 4, and Week 6
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Double Trouble)
Time frame: Baseline, Week 2, Week 4, and Week 6
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Feature Match)
Time frame: Baseline, Week 2, Week 4, and Week 6
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Paired Associates)
Time frame: Baseline, Week 2, Week 4, and Week 6
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Digit Span)
Time frame: Baseline, Week 2, Week 4, and Week 6
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Spatial Planning)
Time frame: Baseline, Week 2, Week 4, and Week 6
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
10 secondary outcomes
Change in Self-Reported Focus
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Attention
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Concentration
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Productivity
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Alertness
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Clarity
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mood
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Fatigue
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Motivation
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Organization
Time frame: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
Related trials for Cognitive Function
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BrainJuice Supplement in people with Cognitive Function and Cognitive Performance, run by BrainJuice at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cognitive Assessment Score (Polygons) (time frame: Baseline, Week 2, Week 4, and Week 6). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.